Scottish Enterprise – Wobble Genomics

Wobble Genomics, a biotechnology company focused on improving cancer outcomes through better diagnosis and therapy selection, presents new data at the 2025 San Antonio Breast Cancer Symposium (SABCS), (December 9-12), in San Antonio, Texas. The data demonstrates the ability to accurately detect HER2 expression in breast cancer, both in solid tumour biopsies and blood samples.

Edinburgh, UK, 6th May, 2025 – Wobble Genomics, a biotechnology company working to improve outcomes in cancer through better diagnosis and therapy selection, via a novel ultra-sensitive cell-free RNA (cfRNA) liquid biopsy diagnostic platform, today announced the appointment of Dr. Dietrich Stephan as Chairman of the Board. Dr. Stephan brings a track record in scaling

Wobble Genomics, a healthcare and biotechnology company at the forefront of long-read RNA sequencing, will today present new data at the San Antonio Breast Cancer Symposium (SABCS) that demonstrates the ability of its technology platform to provide deep biological insights critical for drug discovery and development, building on previous data which established the technology’s strong predictive performance as a diagnostic tool.

UK startup Wobble Genomics is eyeing the breast cancer early detection market with technology that enables it to capture rare and low-abundance RNA transcripts.